We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 04, 2021

Fewer Adverse Renal Effects With NOACs Than Warfarin in Non-Valvular Atrial Fibrillation

Journal of the American Heart Association


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Heart Association
Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis
J Am Heart Assoc 2021 Mar 17;[EPub Ahead of Print], P Sitticharoenchai, K Takkavatakarn, S Boonyaratavej, K Praditpornsilpa, S Eiam-Ong, P Susantitaphong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading